BCRX BioCryst Pharmaceuticals Inc.

BioCryst to Report Third Quarter 2024 Financial Results on November 4

BioCryst to Report Third Quarter 2024 Financial Results on November 4

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will report its third quarter 2024 financial results on Monday, November 4, 2024.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at .

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn.

BCRXW

Contact:

John Bluth





EN
21/10/2024

Underlying

BCRXBioCryst Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCryst Pharmaceuticals Inc.

 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Presents New Real-World Evidence Showing High Adherence and P...

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat) Additional real-world studies show sustained HAE attack rate reduction after initiating ORLADEYO, regardless of C1-INH status, and patient preference for an oral LTP therapy RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced new real-world comparative research on the use of oral, once-daily ORLADEYO® (berotralstat) that found high rates of adherence and persistence for ORLADEYO, similar to the rates observed with two other long...

October 24, 2024 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst to Report Third Quarter 2024 Financial Results on November 4

BioCryst to Report Third Quarter 2024 Financial Results on November 4 RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will report its third quarter 2024 financial results on Monday, November 4, 2024. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available...

October 21, 2024 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst to Present New Real-World Evidence Showing Significant Reduct...

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat) RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reductions in hospitalizations, emergency room visits and use of on-demand therapies,...

October 14, 2024 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis i...

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting –Presentations will demonstrate high adherence and persistence, sustained attack reductions and patient preference for oral, once-daily ORLADEYO for hereditary angioedema– RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present four abstracts on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment o...

October 10, 2024 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 21 newly-hired employees stock options to purchase an aggregate of 71,175 shares, and restricted stock units (RSUs) covering an aggregate of 50,025 shares, of BioCryst common stock. The options and RSUs were granted as of September 30, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were grante...

October 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch